Loading organizations...
Loading organizations...
ArkeaBio is an agricultural bioscience company developing a methane-reducing vaccine to lower greenhouse gas emissions from cattle worldwide. Its core offering is a safe, cost-effective vaccine designed for widespread adoption and efficient integration into farm practices. This biological approach offers a scalable tool for mitigating agricultural emissions.
Founded around 2022, ArkeaBio emerged from the insight that cattle-derived methane is a substantial contributor to global warming. CEO Frank Wooten, an experienced agtech entrepreneur, and CTO Zach Serber, co-founder of Zymergen, lead the company. Their combined scientific and scaling expertise drives development of this crucial environmental technology.
ArkeaBio’s solution benefits farmers with practical integration and economic advantages, governments pursuing climate goals, and food producers striving for sustainability. The company envisions its vaccine becoming a pervasive climate action tool, fostering a future with reduced agricultural emissions supporting the supply of affordable, sustainable beef and dairy.
Arkea Bio has raised $46.0M across 3 funding rounds.
Arkea Bio has raised $46.0M in total across 3 funding rounds.
ArkeaBio is an ag-biotech startup developing a safe, user-friendly, and cost-effective vaccine to reduce methane emissions from ruminants like cattle, targeting the 6% of global greenhouse gas emissions from on-farm livestock.[1][2] The company serves farmers, agribusinesses, and global food systems by integrating its technology into existing vaccination and farming practices for seamless, large-scale deployment across geographies.[1][2][3] It solves the critical problem of enteric methane from ruminants, which contributes around 10% to global warming, offering a scalable solution that improves feed efficiency and delivers economic benefits to producers while combating climate change.[2][5]
With $38.5M in total funding, including a recent $26.5M round, ArkeaBio demonstrates strong growth momentum, backed by prominent investors like Breakthrough Energy Ventures, Rabo Ventures, and Overview Capital.[3][5] Headquartered in Charlestown, MA, the company recently expanded its facilities, signaling operational scaling.[3]
ArkeaBio emerged from the need to address hard-to-abate methane emissions in agriculture, leveraging innovative vaccine technologies pioneered by a team of scientists and entrepreneurs.[2][4] Key leader Zach Serber, co-founder and Chief Technology Officer, brings deep expertise from co-founding Zymergen (industrial microbe engineering for ag and other sectors) and Amyris (biofuels and advanced biology), with 17 publications, 10 patents, Stanford research, and degrees from Columbia, University of Edinburgh, and UCSF.[4] The idea crystallized around creating a realistic, deployable vaccine compatible with global ag practices, marking a pivotal shift toward climate biotech solutions.[1][5]
Early traction came through demonstrations of the world's first methane-reducing cattle vaccine, attracting major backers focused on sustainability and food system transitions.[5] This foundation humanizes ArkeaBio as a mission-driven effort by biotech veterans tackling one of agriculture's biggest environmental challenges.
ArkeaBio stands out in the climate-ag space through these key strengths:
These elements create a "win-win" for farmers, brands, consumers, and the planet, with potential for improved animal welfare.[5]
ArkeaBio rides the climate tech and ag-biotech wave, capitalizing on surging demand for methane abatement amid global net-zero goals, where livestock emissions represent a stubborn 6-10% of GHGs.[2][5] Timing is ideal: intensifying regulations, consumer pressure for sustainable food, and investor focus on "hard-to-abate" sectors favor scalable biotech over less practical alternatives like feed additives.[5] Market forces like rising carbon pricing and cooperative banking initiatives (e.g., Rabo Ventures) amplify adoption, positioning ruminant vaccines as a cornerstone for food system decarbonization.[5]
The company influences the ecosystem by pioneering integration with proven ag practices, inspiring similar innovations and accelerating the shift to low-emission livestock production worldwide.[1][2]
ArkeaBio is poised for commercialization, with its vaccine pathway advancing toward global cattle deployment, potentially slashing ag methane at scale.[5] Trends like AI-driven bioengineering, policy incentives for methane cuts, and supply chain sustainability mandates will propel growth, evolving its role from pioneer to agribusiness standard.[4][5] As backers like Breakthrough Energy Ventures emphasize, this could prevent accelerating emissions, cementing ArkeaBio's influence in future-proofing global food systems—delivering the safe, seamless climate impact promised from day one.[5]
Arkea Bio has raised $46.0M in total across 3 funding rounds.
Arkea Bio's investors include Breakthrough Energy Ventures, Synthesis Capital, AgriZeroNZ, Grantham Foundation, Overview Capital, Rabo Ventures, The51 Food & AgTech Fund.
Arkea Bio has raised $46.0M across 3 funding rounds. Most recently, it raised $7.0M Series A in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $7.0M Series A | Breakthrough Energy Ventures, Synthesis Capital | |
| May 1, 2024 | $27.0M Series A | Breakthrough Energy Ventures | Synthesis Capital, AgriZeroNZ, Grantham Foundation, Overview Capital, Rabo Ventures, The51 Food & AgTech Fund |
| Dec 1, 2022 | $12.0M Seed | Breakthrough Energy Ventures | Synthesis Capital |